{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:06Z","timestamp":1787020086997,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016041","name":"University Hospitals Birmingham Charity","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016041","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Metchley Park Medical Society"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/18\/29\/33554"],"award-info":[{"award-number":["FS\/18\/29\/33554"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/16\/73\/32314"],"award-info":[{"award-number":["FS\/16\/73\/32314"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/19\/16\/34169"],"award-info":[{"award-number":["FS\/19\/16\/34169"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coronary microvascular dysfunction (CMD) is common in end-stage renal disease (ESRD) and is an adverse prognostic marker. Coronary flow velocity reserve (CFVR) is a measure of coronary microvascular function and can be assessed using Doppler echocardiography. Reduced CFVR in ESRD has been attributed to factors such as diabetes, hypertension and left ventricular hypertrophy. The contributory role of other mediators important in the development of cardiovascular disease in ESRD has not been studied. The aim of this study was to examine the prevalence of CMD in a cohort of kidney transplant candidates and to look for associations of CMD with markers of anaemia, bone mineral metabolism and chronic inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-two kidney transplant candidates with ESRD were studied with myocardial contrast echocardiography, Doppler CFVR assessment and serum multiplex immunoassay analysis. Individuals with diabetes, uncontrolled hypertension or ischaemic heart disease were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>7\/22 subjects had CMD (defined as CFVR\u2009&lt;\u20092). Demographic, laboratory and echocardiographic parameters and serum biomarkers were similar between subjects with and without CMD. Subjects with CMD had significantly lower haemoglobin than subjects without CMD (102\u00a0g\/L\u2009\u00b1\u200912 vs. 117\u00a0g\/L\u2009\u00b1\u200911, p\u2009=\u20090.008). There was a positive correlation between haemoglobin and CFVR (r\u2009=\u20090.7, p\u2009=\u20090.001). Similar results were seen for haematocrit. In regression analyses, haemoglobin was an independent predictor of CFVR (\u03b2\u2009=\u20090.041 95% confidence interval 0.012\u20130.071, p\u2009=\u20090.009) and of CFVR\u2009&lt;\u20092 (odds ratio 0.85 95% confidence interval 0.74\u20130.98, p\u2009=\u20090.022).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among kidney transplant candidates with ESRD, there is a high prevalence of CMD, despite the absence of traditional risk factors. Anaemia may be a potential driver of microvascular dysfunction in this population and requires further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-021-02025-2","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T09:04:18Z","timestamp":1619427858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Coronary microvascular dysfunction is associated with degree of anaemia in end\u2010stage renal disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Ashwin","family":"Radhakrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke C.","family":"Pickup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty C.","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Fabritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxy","family":"Senior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Steeds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan N.","family":"Townend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"2025_CR1","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/heartjnl-2019-315138","volume":"105","author":"A Radhakrishnan","year":"2019","unstructured":"Radhakrishnan A, Pickup LC, Price AM, Law JP, Edwards NC, Steeds RP, et al. Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy? Heart. 2019;105:1302\u20139. https:\/\/doi.org\/10.1136\/heartjnl-2019-315138.","journal-title":"Heart"},{"key":"2025_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.amjcard.2013.11.026","volume":"113","author":"S Imamura","year":"2014","unstructured":"Imamura S, Hirata K, Orii M, Shimamura K, Shiono Y, Ishibashi K, et al. Relation of albuminuria to coronary microvascular function in patients with chronic kidney disease. Am J Cardiol. 2014;113:779\u201385. https:\/\/doi.org\/10.1016\/j.amjcard.2013.11.026.","journal-title":"Am J Cardiol"},{"key":"2025_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.kint.2017.07.025","volume":"93","author":"DM Charytan","year":"2018","unstructured":"Charytan DM, Skali H, Shah NR, Veeranna V, Cheezum MK, Taqueti VR, et al. Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage. Kidney Int. 2018;93:375\u201389. https:\/\/doi.org\/10.1016\/j.kint.2017.07.025.","journal-title":"Kidney Int"},{"key":"2025_CR4","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jcmg.2012.06.007","volume":"5","author":"VL Murthy","year":"2012","unstructured":"Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Dorbala S, et al. Coronary vascular dysfunction and prognosis in patients with chronic kidney disease. JACC Cardiovasc Imaging. 2012;5:1025\u201334. https:\/\/doi.org\/10.1016\/j.jcmg.2012.06.007.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.119.043916","volume":"141","author":"N Bajaj","year":"2020","unstructured":"Bajaj N, Singh A, Zhou W, Gupta A, Fujikura K, Byrne C, et al. Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in patients with chronic kidney impairment. Circulation. 2020;141:21\u201333. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.043916.","journal-title":"Circulation"},{"key":"2025_CR6","doi-asserted-by":"publisher","unstructured":"Olsen RH, Pedersen LR, Snoer M, Christensen TE, Ghotbi AA, Hasbak P, et al. Coronary flow velocity reserve by echocardiography: feasibility, reproducibility and agreement with PET in overweight and obese patients with stable and revascularized coronary artery disease. Cardiovasc Ultrasound. 2015;14. https:\/\/doi.org\/10.1186\/s12947-016-0066-3.","DOI":"10.1186\/s12947-016-0066-3"},{"key":"2025_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.kint.2016.06.014","volume":"90","author":"E Rutherford","year":"2016","unstructured":"Rutherford E, Talle MA, Mangion K, Bell E, Rauhalammi SM, Roditi G, et al. Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. Kidney Int. 2016;90:845\u201352. https:\/\/doi.org\/10.1016\/j.kint.2016.06.014.","journal-title":"Kidney Int"},{"key":"2025_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41581-018-0101-8","volume":"15","author":"X Wang","year":"2019","unstructured":"Wang X, Shapiro JI. Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat Rev Nephrol. 2019;15:159\u201375. https:\/\/doi.org\/10.1038\/s41581-018-0101-8.","journal-title":"Nat Rev Nephrol"},{"key":"2025_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/ajh.2008.351","volume":"22","author":"GP Bezante","year":"2009","unstructured":"Bezante GP, Viazzi F, Leoncini G, Ratto E, Conti N, Balbi M, et al. Coronary flow reserve is impaired in hypertensive patients with subclinical renal damage. Am J Hypertens. 2009;22:191\u20136.","journal-title":"Am J Hypertens"},{"key":"2025_CR10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ahj.2003.07.029","volume":"147","author":"M Ragosta","year":"2004","unstructured":"Ragosta M, Samady H, Isaacs RB, Gimple LW, Sarembock IJ, Powers ER. Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries. Am Heart J. 2004;147:1017\u201323.","journal-title":"Am Heart J"},{"key":"2025_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233\u201371.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/ehjci\/jew082","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277\u2013314. https:\/\/doi.org\/10.1093\/ehjci\/jew082.","journal-title":"J Am Soc Echocardiogr"},{"key":"2025_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijcard.2020.08.013","volume":"320","author":"A Radhakrishnan","year":"2020","unstructured":"Radhakrishnan A, Price AM, Pickup LC, Law JP, McGee KC, Fabritz L, et al. Coronary flow velocity reserve and inflammatory markers in living kidney donors. Int J Cardiol. 2020;320:141\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2020.08.013.","journal-title":"Int J Cardiol"},{"key":"2025_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.40","volume":"2","author":"Kidney Disease","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279\u2013335. https:\/\/doi.org\/10.1038\/kisup.2012.40.","journal-title":"Kidney Int Suppl"},{"key":"2025_CR15","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","volume":"341","author":"RA Wolfe","year":"1999","unstructured":"Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725\u201330.","journal-title":"N Engl J Med"},{"key":"2025_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.amjcard.2017.08.006","volume":"120","author":"Y Paz","year":"2017","unstructured":"Paz Y, Morgenstern R, Weinberg R, Chiles M, Bhatti N, Ali Z, et al. Relation of coronary flow reserve to other findings on positron emission tomography myocardial perfusion imaging and left heart catheterization in patients with end-stage renal disease being evaluated for kidney transplant. Am J Cardiol. 2017;120:1909\u201312. https:\/\/doi.org\/10.1016\/j.amjcard.2017.08.006.","journal-title":"Am J Cardiol"},{"key":"2025_CR17","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1681\/ASN.2005030226","volume":"16","author":"PT Vlagopoulos","year":"2005","unstructured":"Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005;16:3403\u201310.","journal-title":"J Am Soc Nephrol"},{"key":"2025_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.15420\/ecr.2015.10.01.12","volume":"10","author":"I Simova","year":"2015","unstructured":"Simova I. Coronary flow velocity reserve assessment with transthoracic doppler echocardiography. Eur Cardiol Rev. 2015;10:12\u20138.","journal-title":"Eur Cardiol Rev"},{"key":"2025_CR19","doi-asserted-by":"crossref","unstructured":"Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease. Kidney Int. 2003;64(Supplement 87):S32\u20139.","DOI":"10.1046\/j.1523-1755.64.s87.6.x"},{"key":"2025_CR20","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1113\/JP272696","volume":"594","author":"SS Jonker","year":"2016","unstructured":"Jonker SS, Davis L, Soman D, Belcik JT, Davidson BP, Atkinson TM, et al. Functional adaptations of the coronary microcirculation to anaemia in fetal sheep. J Physiol. 2016;594:6165\u201374.","journal-title":"J Physiol"},{"key":"2025_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-020-0799-x","volume":"115","author":"P Wischmann","year":"2020","unstructured":"Wischmann P, Kuhn V, Suvorava T, Muessig JM, Fischer JW, Isakson BE, et al. Anaemia is associated with severe RBC dysfunction and a reduced circulating NO pool: vascular and cardiac eNOS are crucial for the adaptation to anaemia. Basic Res Cardiol. 2020;115:1\u201321. https:\/\/doi.org\/10.1007\/s00395-020-0799-x.","journal-title":"Basic Res Cardiol"},{"key":"2025_CR22","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.thromres.2013.03.013","volume":"131","author":"H Gullu","year":"2013","unstructured":"Gullu H, Caliskan M, Caliskan Z, Unler GK, Ermisler E, Ciftci O, et al. Coronary microvascular function, peripheral endothelial function and carotid IMT in beta-thalassemia minor. Thromb Res. 2013;131:e247\u201352. https:\/\/doi.org\/10.1016\/j.thromres.2013.03.013.","journal-title":"Thromb Res"},{"key":"2025_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1590\/S0066-782X2007000500009","volume":"88","author":"JLJ de Souza","year":"2007","unstructured":"de Souza JLJ, Rodrigues ACT, Buck PC, Guallandro SFM, Mady C. Coronary flow reserve in sickle cell anemia. Arq Bras Cardiol. 2007;88:552\u20138.","journal-title":"Arq Bras Cardiol"},{"key":"2025_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1540-8175.2008.00666.x","volume":"25","author":"AG Almeida","year":"2008","unstructured":"Almeida AG, Ara\u00fajo F, Rego F, David C, Lopes MG, Ducla-Soares J. Abnormal myocardial flow reserve in sickle cell disease: a myocardial contrast echocardiography study. Echocardiography. 2008;25:591\u20139.","journal-title":"Echocardiography"},{"key":"2025_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(07)60194-9","volume":"369","author":"A Phrommintikul","year":"2007","unstructured":"Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381\u20138.","journal-title":"Lancet"},{"key":"2025_CR26","first-page":"1205-1205af","volume":"18","author":"R Senior","year":"2017","unstructured":"Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, et al. Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging. 2017;18:1205\u20131205af.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025_CR27","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1016\/j.crvasa.2017.07.008","volume":"60","author":"J Mal\u00edk","year":"2018","unstructured":"Mal\u00edk J, Danzig V, Bedn\u00e1\u0159ov\u00e1 V, Hru\u0161kov\u00e1 Z. Echocardiography in patients with chronic kidney diseases. Cor Vasa. 2018;60:e287\u201395.","journal-title":"Cor Vasa"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02025-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-02025-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02025-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T09:10:42Z","timestamp":1619428242000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02025-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2025"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-02025-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"18 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients included in this analysis were recruited from studies reviewed and approved by a National Health Service Research Ethics Committee [CRIB-FLOW study approved by the West Midlands\u2014Solihull Research Ethics Committee (19\/WM\/0066), RETRACT study approved by the West Midlands\u2014Black Country Research Ethics Committee (18\/WM\/0287)]. The studies were carried out in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LF has received institutional research grants and non-financial support from the European Union, British Heart Foundation, Medical Research Council (UK), DFG and several biomedical companies. LF is listed as an inventor on two patents held by the University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). No other authors have any competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}